Fig. 1

Diverse HIV-1 entry inhibitors span >6000-fold differences in neutralization potency, with BMS-818251 being >20-fold more potent than BMS-626529 (temasvir). a HIV-1 entry inhibitors with common functional groups shown in black and unique features in red. b Neutralization assay of entry inhibitors against thirty HIV-1 isolates from all major HIV-1 clades. c Neutralization data shown as a scatter plot, with the geometric mean shown as horizontal bars. Dotted lines show the detection limits of neutralization assay